French biotech Valneva, which has developed a lineup of traveler vaccines and is starting a late-stage COVID vax effort, is seeking to level up to the Nasdaq with a $100 million IPO. The company is currently listed on the Euronext in Paris as VLA but wants to move on over to the more lucrative US markets, and comes at a time when after years of neglect, vaccine research is all the rage, and with a COVID asset in hand, Valneva the more interesting to investors. Source: Fierce Biotech 12/4/2021